These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28351332)

  • 1. Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.
    Seidi K; Jahanban-Esfahlan R; Zarghami N
    Tumour Biol; 2017 Mar; 39(3):1010428317691001. PubMed ID: 28351332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
    Close A
    Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.
    Chen M; Lei X; Shi C; Huang M; Li X; Wu B; Li Z; Han W; Du B; Hu J; Nie Q; Mai W; Ma N; Xu N; Zhang X; Fan C; Hong A; Xia M; Luo L; Ma A; Li H; Yu Q; Chen H; Zhang D; Ye W
    J Clin Invest; 2017 Oct; 127(10):3689-3701. PubMed ID: 28846068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular targeted therapies in oncology.
    Siemann DW; Horsman MR
    Cell Tissue Res; 2009 Jan; 335(1):241-8. PubMed ID: 18752004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular targeting therapy: potential benefit depends on tumor and host related effects.
    Horsman MR; Bohn AB; Busk M
    Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular disrupting agents in cancer therapy.
    Smolarczyk R; Czapla J; Jarosz-Biej M; Czerwinski K; CichoĊ„ T
    Eur J Pharmacol; 2021 Jan; 891():173692. PubMed ID: 33130277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of tumor endothelial cells and drug delivery.
    Hida K; Maishi N; Sakurai Y; Hida Y; Harashima H
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt B):140-147. PubMed ID: 26626622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the tumor stroma in cancer therapy.
    Anton K; Glod J
    Curr Pharm Biotechnol; 2009 Feb; 10(2):185-91. PubMed ID: 19199950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy.
    Wu XY; Ma W; Gurung K; Guo CH
    J Formos Med Assoc; 2013 Mar; 112(3):115-24. PubMed ID: 23473523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005?
    Raben D; Ryan A
    Clin Lung Cancer; 2005 Nov; 7(3):175-9. PubMed ID: 16354311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to antiangiogenic therapies.
    Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA
    Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis: an update and potential drug approaches (review).
    Abdelrahim M; Konduri S; Basha R; Philip PA; Baker CH
    Int J Oncol; 2010 Jan; 36(1):5-18. PubMed ID: 19956828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions.
    Liang W; Ni Y; Chen F
    Oncotarget; 2016 Mar; 7(13):15444-59. PubMed ID: 26812886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pericytes: a double-edged sword in cancer therapy.
    Meng MB; Zaorsky NG; Deng L; Wang HH; Chao J; Zhao LJ; Yuan ZY; Ping W
    Future Oncol; 2015; 11(1):169-79. PubMed ID: 25143028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.
    Siemann DW
    Cancer Treat Rev; 2011 Feb; 37(1):63-74. PubMed ID: 20570444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor vasculature: the Achilles' heel of cancer?
    Johannessen TC; Wagner M; Straume O; Bjerkvig R; Eikesdal HP
    Expert Opin Ther Targets; 2013 Jan; 17(1):7-20. PubMed ID: 23121690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.